Radiolabelling and cellular binding studies of metformin and indomethacin loaded dual niosome formulations on human colorectal adenocarcinoma cell line

In the current work, film hydration was used for producing indomethacin-and metformin-loaded dual niosomes with a particle size of < 150 nm, a polydispersity index of < 0.5, and a charge of between-30 and-50 mV. [Tc-99m]Tc was used as a radiolabel for all niosome formulations using stannous chloride as reducing agents. Radioactive thin-layer chromatography (RTLC) was used to evaluate the niosome formulations' radiochemical purity (RP) and stability. Next, the cellular binding of reduced/hydrolyzed (R/H)-[Tc-99m]NaTcO4 and [Tc-99m]Tc-labelled niosome formulations was evaluated in human colorectal adenocarcinoma cells. Radiolabelling all niosomes with [Tc-99m]Tc for 15 min at 500 mu g.mL(-1) stannous chloride resulted in successful radiolabelling, with an observed RP of over 95%. The cell binding percentages of [Tc-99m]Tc-labelled niosome formulations in cancer cells were higher than those of R/H-[Tc-99m]NaTcO4. Finally, the recently developed dual-niosome formulations of metformin and indomethacin labelled with [Tc-99m]Tc may prove effective for nuclear medicine imaging.